tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Axsome Therapeutics (AXSM) and Reata Pharmaceuticals (RETA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lemaitre Vascular (LMATResearch Report), Axsome Therapeutics (AXSMResearch Report) and Reata Pharmaceuticals (RETAResearch Report) with bullish sentiments.

Lemaitre Vascular (LMAT)

Barrington analyst Michael Petusky maintained a Buy rating on Lemaitre Vascular today and set a price target of $54.00. The company’s shares closed last Monday at $44.45.

According to TipRanks.com, Petusky is a 4-star analyst with an average return of 8.8% and a 51.0% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, ATI Physical Therapy, and US Physical Therapy.

Lemaitre Vascular has an analyst consensus of Moderate Buy, with a price target consensus of $54.00.

See the top stocks recommended by analysts >>

Axsome Therapeutics (AXSM)

Jefferies analyst Chris Howerton maintained a Buy rating on Axsome Therapeutics today and set a price target of $77.00. The company’s shares closed last Monday at $35.11.

According to TipRanks.com, Howerton has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.0% and a 29.0% success rate. Howerton covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Gemini Therapeutics, and Karuna Therapeutics.

Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $83.50, a 129.0% upside from current levels. In a report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $51.00 price target.

Reata Pharmaceuticals (RETA)

In a report released yesterday, Maury Raycroft from Jefferies maintained a Buy rating on Reata Pharmaceuticals, with a price target of $70.00. The company’s shares closed last Monday at $30.17, close to its 52-week low of $22.71.

Raycroft has an average return of 59.2% when recommending Reata Pharmaceuticals.

According to TipRanks.com, Raycroft is ranked #2486 out of 7918 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Reata Pharmaceuticals with a $58.25 average price target, a 60.7% upside from current levels. In a report issued on March 23, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $91.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LMAT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed